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Abstract
Current drugs to treat African sleeping sickness are inadequate and new therapies are
urgently required. As part of a medicinal chemistry programme based upon the simplification
of acetogenin-type ether scaffolds, we previously reported the promising trypanocidal activity
of compound 1, a bis-tetrahydropyran 1,4-triazole (B-THP-T) inhibitor. This study aims to
identify the protein target(s) of this class of compound in Trypanosoma brucei to understand
its mode of action and aid further structural optimisation. We used compound 3, a diazirine-
and alkyne-containing bi-functional photo-affinity probe analogue of our lead B-THP-T, com-
pound 1, to identify potential targets of our lead compound in the procyclic form T. brucei. Bi-
functional compound 3 was UV cross-linked to its target(s) in vivo and biotin affinity or Cy5.5
reporter tags were subsequently appended by Cu(II)-catalysed azide-alkyne cycloaddition.
The biotinylated protein adducts were isolated with streptavidin affinity beads and subse-
quent LC-MSMS identified the FoF1-ATP synthase (mitochondrial complex V) as a potential
target. This target identification was confirmed using various different approaches. We show
that (i) compound 1 decreases cellular ATP levels (ii) by inhibiting oxidative phosphorylation
(iii) at the FoF1-ATP synthase. Furthermore, the use of GFP-PTP-tagged subunits of the
FoF1-ATP synthase, shows that our compounds bind specifically to both the α- and β-sub-
units of the ATP synthase. The FoF1-ATP synthase is a target of our simplified acetogenin-
type analogues. This mitochondrial complex is essential in both procyclic and bloodstream
forms of T. brucei and its identification as our target will enable further inhibitor optimisation
towards future drug discovery. Furthermore, the photo-affinity labeling technique described
here can be readily applied to other drugs of unknown targets to identify their modes of action
and facilitate more broadly therapeutic drug design in any pathogen or disease model.
Author summary
Millions of people are at risk of developing African sleeping sickness through infection
with the parasite Trypanosoma brucei, which is fatal if untreated. Current therapies are
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antiquated and inadequate, requiring hospitalization to deliver them through complex
regimens, thus new effective, cheap and easy to administer therapies are urgently required.
We recently reported the generation of a new compound that is selectively active against
the parasite responsible for the disease, but its mechanism of action was unknown. This
body of work identifies the specific target within the parasite as the essential FoF1-ATP
synthase (mitochondrial complex V), first by analysing the proteins bound to a tagged
analogue of our active compound (in a process known as photo-affinity labelling), and
secondly by determining the effects of our active compound on cellular metabolism. With
the target now identified work can begin to improve inhibitor potency and selectivity with
the aid of rational drug design and structural optimisation towards future drug discovery.
Introduction
Protozoan parasites of the Trypanosoma genus cause widespread disease and death across
large regions of the developing world. In sub-Saharan Africa Trypanosoma brucei gambiense
and T. b. rhodesiense are the causative agents of human African trypanosomiasis (HAT, or
African sleeping sickness) in humans while several species cause disease in livestock and wild
animals, creating a major socio-economic burden to the African continent. The parasites are
spread through the bites of infected tsetse flies and, if left untreated, infection is usually fatal.
Over 65 million people who live in the tsetse fly habitat are at risk of infection and each year
there are an estimated 15–20,000 new cases [1].
In the early 1900’s African trypanosomes became one of the first subjects of “modern drug
discovery” when Paul Ehrlich, following his observations on differential cell stains, hypothe-
sised that some molecules could be developed to target pathogens but not their hosts (a term
he coined “chemotherapy”), and screened a library of synthetic dyes in trypanosome-infected
animals to find a “magic bullet” [2,3]. Through a combination of rational synthetic chemistry
and phenotypic screening his pioneering work led to the discoveries by others of suramin in
1917 and melarsoprol in 1949 [4], both of which are still front-line drugs for the treatment of
early stage (suramin) and late stage (melarsprol) infection by T. b. rhodesiense [5]. Pentamin-
dine, which is currently the first-line treatment for early stage infection by T. b. gambiense [5],
was likewise developed from the anti-diabetic synthalin in 1937 [6,7]. However, HAT has been
neglected over the past half century and all of these antiquated non-oral drugs are difficult to
administer, are sometimes ineffective and are themselves toxic, often causing undesirable side
effects with melarsoprol causing the death of up to 5% of those treated [5,8]. Furthermore,
melarsoprol resistance is a growing issue [9–14] and new drugs are therefore urgently needed,
particularly for late stage infection. Despite their antiquity and widespread use, the targets and
modes of action of these currently used drugs are poorly understood, making it difficult to
design to safer analogues. Investment from the pharmaceutical industry has been slow in
forthcoming for this and related neglected diseases, which affect many of the poorest and most
underdeveloped countries in the world, and efforts so far have been driven instead by charities
and non-profit organisations.
Advances in automated liquid handling, cell culture and detection technology has allowed
researchers and the pharmaceutical industry to return to phenotypic screening-based prac-
tices, as those pioneered by Ehrlich, for the latest drug discovery efforts. We recently reported
the total synthesis and trypanocidal activity of the acetogenin, chamuvarinin [15,16] and non-
natural bis-tetrahydropyran 1,4-triazole (B-THP-T) analogues thereof including compound 1
([17]; Fig 1A) using a phenotypic screening approach. Acetogenins are a family of over 400
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structurally related fatty acid-derived natural products isolated from tropical plants of the
Annonaceae family (for review, see [18]), and characteristically bear one to three tetrahydro-
pyran (THP) and/or tetrahydrofuran (THF) rings flanked by a terminal γ-lactone head and a
hydrophobic tail. Many members have been reported to display high inhibition of mitochon-
drial complex I [19–21], making them cytotoxic to a wide range of organisms [22,23], and
their particularly high potency against ATP-hungry tumour cells (reviewed in [24]) has led to
their investigation as potential anti-cancer chemotherapeutics; despite mammalian cells
requiring complex I activity, pre-clinical trials with select acetogenins are encouraging, with
some proving as effective and selective as Taxol, a first-line treatment for some cancers, at
reducing solid tumours in mice [25]. Cytotoxic activities vary among acetogenins and between
cell lines/organisms but several studies have demonstrated that both γ-lactone and THP/THF
moieties are essential for complex I inhibition [26–28]. Intriguingly, chamuvarinin and
B-THP-Ts are toxic to procyclic form (PF) and bloodstream form (BSF) T. brucei [15–17] with
EC50 values in the low micromolar range (Fig 1), however, complex I is not essential in either
form of the parasite [29,30], and our B-THP-Ts lack the terminal γ-lactone indicating that our
compounds must have a different mode of action in kinetoplastids. In order to further opti-
mise the potency and selectivity of our trypanocidal B-THP-T compounds this study set out to
determine their precise target(s) in T. brucei.
The identification of targets of lead compounds is often necessary to allow subsequent lead
optimisation, but target identification is a major bottleneck in the drug discovery pipeline fol-
lowing phenotypic screens. Photo-affinity labelling provides an elegant solution by covalently
attaching a bifunctional photo-affinity probe analogue of the lead compound to the target for
its ultimate detection (for review see [31] and Fig 1A & 1B) and can readily be achieved by
incorporating photoreactive and reporter moieties to the lead compound. Azides, benzophe-
nones and diazirines make excellent photoreactive substituents as they decompose upon UV-
irradiation to form short-lived reactive nitrenes, diradicals or carbenes respectively, which rap-
idly react with neighbouring molecules to form covalent bonds. Hence, by photo-activating
the probes once they have been trafficked to their targets, these protein targets can be preferen-
tially labelled. Several radiolabled leads have been functionalised with photoreactive azides
[32,33], benzophenones [34] or diazirines [21,35,36] and their targets detected by autoradio-
graph following protein separation, i.e. SDS-PAGE. A similar, but radiolabel free, methodol-
ogy has also been employed by functionalising an inhibitor with both a photoreactive diazirine
and a fluorescent reporter moieties, allowing the target to be visualised both in gel and within
intact cells, thus adding the benefit of target localisation determination. The major drawback
of using a radiolabel or fluorescent tags is that, while it allows one to visualise the target, it
rarely provides a means to isolate or identify the target. Thus, many [37–44] have used bi-func-
tional photo-affinity probes containing a photoreactive moiety coupled with biotin affinity tag
which allows the photo-affinity labelled target to be purified from other proteins using strepta-
vidin beads and identified by tandem mass spectrometry. More versatile yet is the functionali-
zation of the lead compound with photo-affinity group and alkyne handle which allows the
subsequent attachment of any desired reporter, such as fluorophore [45–47] or biotin [48,49]
using the Cu(II)-catalysed azide-alkyne cycloaddition, also known as the “click reaction” [50]
once the photo-affinity probe had been UV-cross-linked to its target.
To identify the target(s) of B-THP-T compounds we synthesised two photo-affinity probe
analogues of our lead compound (Fig 1A, synthesis to be reported elsewhere): mono-func-
tional compound 2 contains a photoreactive diazirine, but has no reporter capability; while bi-
functional compound 3 contains the same photoreactive diazirine and an alkyne handle to
allow subsequent identification through appendage with biotin affinity or Cy5.5 fluorescent
reporter tags. Importantly, the diazirine and alkyne encompass only minor changes to our lead
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005886 September 5, 2017 3 / 28
Fig 1. Labelling and detection of B-THP-T target(s). (A) Structures of chamuvarinin and simplified analogues thereof as probes used in this study and
their respective toxicity in selected cell lines. Bi-functional compound 3 contains a diazirine (blue) to cross-link the compound to its target and an alkyne
handle (red) to which an azide-containing reporter probe can be added. Mono-functional compound 2 contains the diazirine to cross-link to its target but
lacks the alkyne handle and cannot be appended with an azide reporter probe. Lead B-THP-T, compound 1, lacks both diazirine and alkyne. The additional
functional groups on compounds 2 and 3 are minor alterations, which have little effect on inhibitor potency. (B) Overview of the in vivo pulse-chase photo-
affinity labelling procedure. B-THP-T were incubated with live PF T. brucei cells and trafficked to their targets. Following UV-irradiation, only compounds
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
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B-THP-T, compound 1, and all compounds show similar levels of toxicity (Fig 1 and S1 Fig)
indicating that the photo-affinity probes work through the same mode of action and are thus
suitable for target identification purposes. Here we employed an in vivo pulse-chase photo-
affinity labelling methodology to covalently attach bi-functional compound 3 to its target
within its biological context and, coupled with liquid chromatography-tandem mass spectrom-
etry identified proteins that are potential targets of B-THP-T compounds. Subsequently, using
several metabolic and biochemical assays with lead B-THP-T, compound 1, we validated two
of those protein hits as binding partners and now allows us to begin work to optimise the
potency and selectivity of our inhibitors towards these targets. Furthermore, it demonstrates
the strength of this photo-affinity labelling technique, which can be readily applied to any drug
discovery program to accelerate the drug discovery process.
Results and discussion
Compound 3 photo-affinity labels target(s) specifically
To identify the target(s) of the trypanocidal B-THP-T, compound 1, we developed compound
3, a bi-functional photo-affinity probe analogue of compound 1 (Fig 1A and 1B, synthesis to
be published elsewhere). In addition to the core structure of compound 1, compound 3 con-
tains a diazirine to covalently bind to its target upon UV-activation and an alkyne handle to
which an azide reporter, such as a fluorophore or affinity tag can subsequently be added via
copper catalysed azide-alkyne cycloaddition, often referred to as the ‘click reaction’ [31,50]. As
a negative control, we also developed the mono-functional compound 2 (Fig 1A), which con-
tains the diazirine, but lacks the alkyne and therefore cannot conjugate the azide reporter. Cru-
cially, the addition of the diazirine and alkyne moieties encompass only minor changes to the
parent molecule and have minimal effect on overall compound potency (Fig 1A and S1 Fig),
suggesting that compounds 1–3 have the same mode of action and that photo-affinity probe 3
is therefore suitable for the identification of target(s) of our B-THP-T compounds.
Compounds 1–3 were pulse-chased to their targets in live PF T. brucei cells and UV-irradi-
ated to covalently attach the diazirine-containing compounds to their targets (Fig 1B). The
pulse-chase methodology was employed rather than labelling in cell lysates so that inhibitors
would be trafficked to their target(s) and labelling would therefore occur in its biological con-
text, minimising the likelihood of identifying high affinity targets that do not form in vivo. Once
the extracted proteins had been subjected to azide-alkyne cycloaddition with Cy5.5-azide, pro-
teins that had been appended with Cy5.5 were detected by SDS-PAGE coupled with fluores-
cence imaging (Fig 1C). As expected, when either the diazirine or alkyne were absent (as in
compounds 1 and 3) no proteins fluoresced as there was no mechanism for them to covalently
bind the Cy5.5 reporter molecule, and this absence of fluorescence indicated that there was
minimal non-specific binding of Cy5.5 reporter to cellular proteins. Proteins only incorporated
the Cy5.5 reporter tag when diazirine and alkyne were both present on the B-THP-T compound
(i.e., with the bi-functional compound 3, lane 3 of Fig 1C) confirming their essentiality for
photo-affinity labelling of protein targets. 18 protein bands were detected to varying degrees,
with most prominent bands around 70 and 55 KDa, suggesting major targets of these sizes.
containing a diazirine (i.e. compounds 2 and 3) could cross-link with target proteins. The subsequent “click reaction” appended the conjugated B-THP-T
with a reporter probe as long as an alkyne handle was present (i.e. on compound 3). Refer to the experimental section for details. (C) Detection of
Cy5.5-tagged proteins following photo-affinity labelling. Proteins were separated by SDS-PAGE and conjugated Cy5.5 was detected at 700 nm. Lanes 1–3
correspond to usage of compounds 1–3 respectively. Several proteins in lane 3 were conjugated with Cy5.5 via labelling with bi-functional compound 3. No
Cy5.5 conjugation was detected in lanes 1 or 2 where the B-THP-T used lacked diazirine and/or alkyne handle, indicating that reporter labelling is specific to
bi-functional compound 3.
https://doi.org/10.1371/journal.pntd.0005886.g001
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Protein target(s) are localised to the mitochondria
To identify the cellular compartments housing B-THP-T protein targets, Cy5.5-azide was
“clicked on” to B-THP-T-conjugated proteins in fixed whole cells following pulse-chase
photo-affinity labelling, and detected by fluorescence microscopy (Fig 2). Bi-functional com-
pound 3 without UV-conjugation and lead compound 1, were used as negative controls. As
with Fig 1C, Cy5.5 labelling only occurred when compound 3 was cross-linked by UV-activa-
tion, again indicating specific labelling of target proteins(s). Cy5.5 labelling was absent from
the nucleus, but showed good co-localisation with the MitoTracker staining, suggesting that
B-THP-T compounds predominantly target proteins associated with the mitochondria.
Pull-down hits involve ATP production
Next a series of pull-down experiments were performed to identify the proteins tagged with
bi-functional photo-affinity probe, compound 3. For pull-down of the target(s), biotin azide
Fig 2. Localisation of B-THP-T target(s). PF T. brucei cells were in vivo pulse-chase photo-affinity labelled with lead B-THP-T compound 1 or bi-
functional compound 3. Cells were imaged following in-cell Cy5.5 cycloaddition. Cy5.5 labelling (green) was absent when bi-functional tags were absent
(compound 1) or when compound 3 was not UV-activated, indicating that the Cy5.5 labelling observed with UV-activated bi-functional compound 3 is
specific. Cy5.5-labelled proteins co-localise with MitoTracker (red), indicating that B-THP-T compounds target mitochondrial proteins.
https://doi.org/10.1371/journal.pntd.0005886.g002
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
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was used as reporter and “clicked” on to the B-THP-T-labelled proteins following the same
pulse-chase in vivo photo-affinity labelling methodology as used above. Tagged proteins were
then enriched with streptavidin-agarose, digested on-bead with trypsin, analysed by LC-
MSMS, and identified through Mascot searches of the T. brucei proteome. Compound 1 and
mono-functional compound 2, which both lacked the alkyne handle required for biotin-azide
cycloaddition, were used as negative controls and any proteins pulled down with either of
these were eliminated from the bi-functional compound 3 list of potential protein targets as
they represented proteins bound non-specifically to the beads rather than through the biotin-
streptavidin interaction. Following elimination of low scoring proteins and unknown proteins
(which would be difficult to validate in the timeframe of this study due to their unknown
nature), twenty-five T. brucei proteins were identified as potential targets in three replicate
pull-downs from whole cell protein extracts (S1 Table). Of those, seventeen (68%) utilised
nucleotides as a co-factor, indicating that B-THP-Ts may mimic nucleotides. As localisation
studies indicated the target was primarily localised in the mitochondria, attention was focused
on the six mitochondrial proteins identified in the pull-down data (Table 1). Pleasingly, bands
corresponding to proteins of the masses in Table 1 appear to be Cy5.5-labelled via compound
3 cross-linking in lane 3 of Fig 1C, with the most intense bands (~70 KDa and ~55 KDa)
matching closely with the masses of two of the top three hits (72 KDa mitochondrial heat
shock protein 70, mHSP70; and 56 KDa ATP synthase F1 β-subunit). While this supports the
likelihood that the proteins identified in Table 1 were captured via the streptavidin-biotin/
compound 3 interaction rather than non-specific interaction with the beads, the list only
serves as a guide and each of the hits needs to be validated before being identified as a bona-
fide target. The most intense Cy5.5-labelled band in Fig 1C matched the mass the top-scoring
hit in Table 1 (72 KDa mHSP70), which is under investigation as a B-THP-T target and will
be reported elsewhere. Of the remaining five mitochondrial pull-down hits, four (hits 2–5)
have roles in the production of ATP through proline metabolism (Fig 3) and are the subject of
further investigation herein as they can be validated or eliminated through a series of related
follow-up assays.
Proline is one of the principle amino acids used as a carbon source for PF T. brucei in the
insect midgut [51,52]. It is taken into the PF mitochondrion and converted to pyruvate
through eight enzymatic steps, and then further catabolised to alanine or acetate end products
(Fig 3, [53]). ATP is produced at two points during this process: first through substrate-level
phosphorylation at succinyl-CoA synthetase (Fig 3, step 5) as intermediate succinyl-CoA is
converted to succinate by succinyl-CoA synthetase; and second through oxidative phosphory-
lation (the coupling of the electron transport chain (ETC) with ATP production) at the FoF1-
Table 1. Mitochondrial proteins identified as potential targets of B-THP-T compounds by biotin pull-down / LC-MSMS.
Hit Protein Mass Nucleotide Score Sequences %
(KDa) Cofactor Tot Sig Coverage
1 Mitochondrial heat shock 70 kDa protein (MHSP70) 72 ATP 639 19 16 28
2 Dihydrolipoamide succinyltransferase (DLST) 42 CoA 326 7 7 21
3 ATP synthase F1 β-subunit 56 ADP 222 3 3 7
4 δ -1-pyrroline-5-carboxylate dehydrogenase (δPCDH) 63 NAD 207 7 6 14
5 ATP synthase F1 α-subunit C-terminal chain 44 * ADP 158 6 3 13
6 L-threonine 3-dehydrogenase (ThrDH) 37 CoA 148 4 3 12
* In trypanosomatids the F1 α-subunit is expressed as a 64 KDa protein and cleaved into a 20 KDa N-terminal and 44 KDa C-terminal chains. Only the 44
KDa C-terminal chain was detected in our pull-downs.
https://doi.org/10.1371/journal.pntd.0005886.t001
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ATP synthase (mitochondrial complex V) as the reduction of succinate to fumarate by mito-
chondrial complex II feeds electrons into the electron transport chain (ETC). Two of the pull-
down hits, δ-pyrroline-5-carboxylate dehydrogenase (δPCDH, hit 4 in Table 1, Fig 3) and
Fig 3. Proline metabolism in PF T. brucei and reactions catalysed by potential B-THP-T targets. PF T.
brucei grown in glucose-free medium are reliant on proline as a carbon source and enzymes of an incomplete
TCA-cycle are used to metabolise it to alanine and actetate (shown in blue): 1, proline dehydrogenase; 2,
δpyrroline-5-carboxylate dehydrogenase (δPCDH); 3, L-alanine aminotransferase; 4, a-ketoglutarate
dehydrogenase complex (of which dihydrolipoamide succinyltransferase, DLST, is a component); 5, succinyl-
CoA synthetase; 6, mitochondrial complex II; 7, fumarase; 8, malate dehydrogenasemalic enzyme; 9,
pyruvate dehydrogenase complex; 10, acetate:succinate CoA-transferase. Substrate-level phosphorylation
occurs with the conversion of succinyl-CoA to succinate at succinyl-CoA synthetase (step 5). Mitochondrial
complex II reduces succinate to fumarate at step 6 and passes electrons into the electron transport chain
(represented in green) via ubiquinol (Q). Complex III passes the electrons to cytochrome c (C), and complex
IV passes them from cytochrome c to molecular oxygen forming water. Complexes III and IV together export
six protons (green dashed line) for each molecule of succinate reduced, and the FoF1-ATP synthase (complex
V) generates ATP by importing four protons, making 1.5 molecules of ATP for every molecule of succinate
reduced. The sites of action of oxidative phosphorylation inhibitors are shown. Figure adapted from [19].
Roles of four of the six-mitochondrion pull-down hits are shown in red italic numbers.
https://doi.org/10.1371/journal.pntd.0005886.g003
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
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dihydrolipoamide succinyltransferase (DLST, hit 2 in Table 1, Fig 3) have roles prior to sub-
strate-level ATP production, while two other hits, the F1 α- and β-subunits (hits 5 and 3
respectively in Table 1, Fig 3), form the ADP-binding regulatory and ADP-binding catalytic
domains respectively of the FoF1-ATP synthase and have direct roles in ATP production from
oxidative phosphorylation downstream of substrate-level ATP production. Targeting of any of
these four hits by B-THP-T compounds would consequently impact cellular ATP production
to varying extents. Therefore, a series of biochemical phenotypic studies were undertaken to
validate or exclude the pull-down of these four hits.
B-THP-Ts inhibit cellular ATP production
We first set out to determine if B-THP-T compounds affected cellular ATP levels. PF T. brucei
were incubated in buffered PBS with/without proline as the sole carbon source and various
inhibitors for 2 h. Cells were harvested and their ATP content was determined by biolumines-
cence assay. Two ETC inhibitors were used as positive control: malonate is a competitive
inhibitor of mitochondrial complex II and prevents the reduction of succinate to fumarate and
entry of electrons to the ETC; and antimycin A (AA) is a mitochondrial complex III inhibitor,
which prevents the transfer of electrons to cytochrome c and ubiquinone recycling. Both ETC
inhibitors significantly inhibited cellular ATP production by 62 ± 15% and 71 ± 9% respec-
tively (Fig 4), consistent with them shutting down oxidative phosphorylation but leaving
upstream substrate-level phosphorylation at succinyl-CoA synthetase unaffected. Compound
1 inhibited ATP production in a dose-response manner to similar levels (by 55 ± 6%), support-
ing the hypothesis from pull-down data that its target is involved in the ATP production path-
way from proline.
Fig 4. B-THP-Ts decrease cellular ATP levels. PF T. brucei cells were incubated in buffered PBS with/without proline (as sole carbon
source) and various inhibitors (concentrations indicated) incubated for 2 h, after which cells were harvested and cellular ATP levels were
monitored by bioluminescence assay. Key: NS, no substrate; NI, no inhibitor control; Malonate (complex II inhibitor) AA, antimycin A (AA,
complex III inhibitor). Background relative light units (RLU) were subtracted from measurements and % ATP production normalised to the
no inhibitor control. Data were averaged from two independent experiments, each performed in duplicate (n = 4). Error bars show standard
deviations. T-tests were performed against no inhibitor controls (black asterisks) and compound 1 used at 10 μM (grey open circles) and
significance values presented: p < 0.0005 (*** / ˚˚˚), p < 0.005 (** / ˚˚), p < 0.05 (* / ˚). The B-THP-T compound 1 significantly reduces
ATP levels in a dose-response manner to levels indistinguishable from known inhibitors of oxidative phosphorylation.
https://doi.org/10.1371/journal.pntd.0005886.g004
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
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B-THP-Ts inhibit ATP production at oxidative phosphorylation
We next sought to identify the point at which ATP production was blocked using digitonin-
permeabilised cells. Digitonin permeabilises the plasma membrane of trypanosomatids, but
crucially, leaves the glycosomes and mitochondria intact and fully functional, allowing them to
be probed with compartment-specific ATP-yielding substrates [54,55]. Digitonin-permeabi-
lised PF T. brucei were probed with succinate, which is readily transported across the PF T.
brucei mitochondrial membrane by the dicarboxylic acid carrier [56] and can yield only oxida-
tive phosphorylation-derived ATP through the FoF1-ATP synthase (complex V). As expected,
the mitochondrial complex II inhibitor, malonate, completely eliminated all ATP production
from succinate, while downstream inhibitors antimycin A (AA), complex V inhibitor oligomy-
cin A (OA) and protonophore 2,4-dinitrophenol (DNP) almost abolished ATP production
(Fig 5A). Lead B-THP-T, compound 1, decreased ATP production from succinate to similar
levels, while rotenone and salicylhydroxamic acid (SHAM), which inhibit the ETC at different
entry points and are therefore irrelevant inhibitors, had no significant effect, indicating that
compound 1 inhibits oxidative phosphorylation, and is consistent with the F1 α- and/or β-sub-
units being targets. However, this result on its own does not confirm that the F1 subunits are
targets, as inhibition of substrate (ADP or succinate) uptake or any of the mitochondrial com-
plexes could have the same effect.
Next, mitochondria were incubated with α-ketoglutarate, which is also taken into the mito-
chondria by the dicarboxylic acid carrier, to examine the effects of B-THP-T compounds on
substrate-level phosphorylation. The multiprotein α-ketoglutarate dehydrogenase complex, of
which dihydrolipoamide succinyltransferase (DLST, hit 2 in Table 1) is a component, converts
α-ketoglutarate into succinyl-CoA (Fig 3), allowing succinyl-CoA synthetase to generate sub-
strate-level ATP. In addition, electrons from resulting succinate can enter the ETC to generate
oxidative phosphorylation-derived ATP. As complexes III-IV export six protons for every α-
ketoglutarate metabolised and the FoF1-ATP synthase imports only four protons with every
ATP synthesised, each mole of α-ketoglutarate can yield 1.5 moles ATP through oxidative
phosphorylation. Thus, 40% of the ATP produced from α-ketoglutarate is by substrate-level
phosphorylation and 60% is through oxidative phosphorylation. With α-ketoglutarate as sub-
strate, the four oxidative phosphorylation inhibitor controls only blocked up to 48 ± 12% of
ATP production (Fig 5B) as they were unable to block upstream substrate-level ATP produc-
tion by succinyl-CoA synthetase. Compound 1 inhibited ATP production by 67 ± 13%,
achieving a significantly lower level of inhibition than that achieved when succinate was used
as substrate (Fig 5A), suggesting that the blockade is not due to inhibition of substrate uptake,
but is due to inhibition of one of the mitochondrial complexes. The greater level of inhibition
achieved by compound 1 over the other oxidative phosphorylation inhibitors suggests that
compound 1 may also be inhibiting substrate-level phosphorylation to some extent, and is,
perhaps, an indication that compound 1 also targets DLST (pull-down hit 2 in Table 1). How-
ever, the more significant effect of compound 1 is, by far, on oxidative phosphorylation and
the F1 subunits are therefore likely to be more significant targets.
Use of the cytosolic oxidative phosphorylation substrate glycerol-3-phosphate (Gly-3P)
allowed us to establish whether substrate uptake was a target of our compounds. Mitochon-
drial Gly-3P dehydrogenase (mGPDH) is located in the intermembrane space of the mito-
chondrion and converts cytosolic Gly-3P into dihydroxyacetone phosphate (DHAP) while
transferring electrons to the ETC via ubiquinone [54]. Gly-3P can therefore be used to probe
oxidative phosphorylation at a different entry point from succinate and is not reliant on
substrate uptake. When Gly-3P was used as substrate, malonate had no effect on ATP produc-
tion (Fig 5C) as complex II is irrelevant at this ETC entry point. Likewise, other irrelevant
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Fig 5. Inhibition of ATP production in digitonin-permeabilsed cells. (A-C) Digitonin-permeabilised PF T.
brucei were probed with substrates in the presence of inhibitors and resulting ATP production quantified by
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inhibitors rotenone and SHAM had no effect on ATP production. However, AA, OA and
DNP, which all inhibit oxidative phosphorylation downstream of mGPDH and mitochondrial
complex II, reduced ATP production by 75 ± 14%, 65 ± 21% and 67 ± 13% respectively. The
inability of oxidative phosphorylation inhibitors to abolish ATP production from Gly-3P has
been noted previously [54] and may be the result of glycolytic ATP production following gly-
cosomal uptake of Gly-3P or its product, DHAP. Lead B-THP-T, compound 1, acted similarly,
inhibiting ATP production by 82 ± 16%. This confirmed that inhibition of oxidative phosphor-
ylation by compound 1 is not due to inhibition of substrate uptake as Gly-3P is not taken into
the mitochondrion and, furthermore, it indicates that the inhibition is downstream of electron
entry to the ETC, or more specifically, that compound 1 inhibits one of complexes III-V.
The potency of lead B-THP-T, compound 1, was determined against oxidative phosphory-
lation in dose-response assays in digitonin-permeabilised PF T. brucei. The IC50 of compound
1 was 57 ± 15μM and 39 ± 5 μM when succinate and Gly-3P were used respectively (Fig 5D).
Although these values are higher than in whole cell EC50 assays (8.4 μM), it is noteworthy that
they cannot be compared directly as the concentrations of proteins and substrates differ greatly
between experiments, as do the time-scales of the experiments: digiton-permeabilised cells
were plated at over 1000-fold greater density than live cells and used an acute incubation (30
min) rather than the chronic 72 h incubation of the cell viability assay.
B-THP-Ts block oxidative phosphorylation at the FoF1-ATP synthase,
mitochondrial complex V
To determine which mitochondrial complex of oxidative phosphorylation was targeted by B-
THP-T compounds, their effects on the mitochondrial membrane potential (Δψm) were moni-
tored in live PF T. brucei (Fig 6A). MitoTracker Red CMXRos, like tetramethylrhodamine and
safranine, accumulates in active mitochondria and the degree of accumulation is dependent
on the Δψm [57,58], however, accumulation of MitoTracker Green FM is independent of the
Δψm and the ratio of red/green uptake can therefore be used to determine the Δψm normalised
to the number and size of mitochondria present [59]. In PF T. brucei mitochondrial complexes
bioluminescence assay. See experimental section for details. Inhibitors were used at saturating
concentrations to ensure that relevant enzyme activities were ablated. Key: NS, no substrate; NI, no inhibitor;
SHAM, salicylhydroxamic acid (TAO inhibitor at 100 μM); Rotenone (complex I inhibitor at 100 μM); Malonate
(complex II inhibitor at 5 mM); AA, antimycin A (complex III inhibitor at 200 μM); OA, oligomycin A (complex V
inhibitor at 200 μM); DNP, 2,4-dinitrophenol (protonophore at 1 mM); Comp.1, compound 1 at 200 μM.
Background relative light units (RLU) were subtracted from measurements and % ATP production normalised
to the no inhibitor control. Data were averaged from three independent experiments, each performed in
quadruplicate. Error bars show standard deviations. T-tests were performed against no inhibitor controls
(black asterisks) and compound 1 (grey open circles) and significance values presented: p < 0.00005 (*** / ˚
˚˚), p < 0.0005 (** / ˚˚), p < 0.005 (* / ˚). (A) Succinate was used as a substrate to generate ATP solely through
oxidative phosphorylation (OxPhos). Oxidative phosphorylation inhibitors malonate, AA, OA and DNP virtually
eliminated all ATP production. Compound 1 almost eliminated ATP production and was indistinguishable
from inhibitors of oxidative phosphorylation, suggesting that it too inhibits oxidative phosphorylation. (B) α-
ketoglutarate yields 40% ATP through substrate-level phosphorylation (SubPhos) and 60% through oxidative
phosphorylation. Malonate, AA, OA and DNP inhibit oxidative phosphorylation, but not substrate-level
phosphorylation. Compound 1 acted similarly, albeit with a minor additional effect (possibly on DLST, which
was also a pull-down hit), suggesting oxidative phosphorylation is its major target. (C) Gly-3P acts as an
alternative entry site to the electron transport chain yielding ATP through oxidative phosphorylation and the
glycosome (GlyPhos). Malonate has no effect, as it acts at a different entry point. AA, OA and DNP inhibit
oxidative phosphorylation, but not glycosomal phosphorylation. There is no significant difference between
compound 1 and oxidative phosphorylation inhibitors, suggesting compound 1 acts downstream of complex
II. (D) IC50 determination of compound 1 in digitonin-permeabilised cells when succinate (57.3 ± 14.5 μM) or
Gly-3P (39.2 ± 4.6 μM) is used as substrate. The efficacy of compound 1 was similar for both substrates
indicating that blockade is downstream of them both.
https://doi.org/10.1371/journal.pntd.0005886.g005
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III-IV generate a Δψm by pumping protons out of the mitochondrion during the ETC (Fig 3),
and thus ETC inhibitors (malonate or AA) prevent proton export and decrease the Δψm (Fig
6B). Conversely, mitochondrial complex V (FoF1-ATP synthase) uses this potential to generate
ATP as it pumps protons back in (Fig 3), so inhibition of complex V by OA prevents proton
import and elevates the Δψm (Fig 6B and [58]). Similarly, compounds 1 and 3 elevated the
mitochondrial membrane potential (by 2-3-fold), confirming that they, like OA, reduce oxida-
tive phosphorylation by the inhibition of the FoF1-ATP synthase.
F1 α- and β-subunits are both targeted by B-THP-T compounds
The F1 α- and β-subunits of the FoF1-ATP synthase were both identified as potential B-THP-T
targets through biotin pull-down (Table 1), and the FoF1-ATP synthase was shown above to be
inhibited by lead B-THP-T compound 1, but to confirm whether both, or just one of the F1
subunits is a target of our compounds, we generated cell lines endogenously expressing α- or
Fig 6. Effects of compounds on mitochondrial membrane potential. PF T. brucei were incubated with
inhibitors and MitoTracker Red CMXRos, which is an indicator of the mitochondrial membrane potential
(Δψm). (A) MitoTracker-loaded cells were imaged to qualitatively detect differences in the Δψm. Complex III
inhibitor, antimycin A (AA at 2 μM) noticeably reduced MitoTracker Red CMXRos uptake, while the FoF1-ATP
synthase (complex V) inhibitor oligomycin A (OA at 2 μM) and compound 1 at 40 μM clearly enhanced
MitoTracker Red CMXRos uptake as compared with the uninhibited control. (B) Fluorescence of MitoTracker-
loaded cells were quantified using a microplate reader and normalised to MitoTracker green fluorescence.
Data were consistent with microscope observations in which inhibitors of the electron transport chain such as
Antimycin A (AA at 2 μM), or protonophores such as 2,4-dinitrophenol (DNP at 1 mM) decrease the
mitochondrial membrane potential (Δψm), while inhibitors of the FoF1-ATP synthase such as Oligomycin A
(OA at 2 μM) elevate the Δψm. Compounds 1 and 3 at 40 μM elevated the Δψm indicating that they, like OA,
target the FoF1-ATP synthase.
https://doi.org/10.1371/journal.pntd.0005886.g006
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β-subunits with C-terminal GFP-PTP tags. The PTP affinity tag comprises epitopes for pro-
teins C and A separated by a TEV protease cleavage site for efficient purification of the target
protein and the cloning methodology facilitates recombination within the endogenous tar-
geted gene rather than exogenous integration, allowing for endogenous levels of expression
[60]. The endogenous expression produces tagged protein at physiological levels, allowing it to
be trafficked and form complexes in the same way as untagged endogenously expressed pro-
tein, as previously demonstrated through the purification of intact FoF1-ATP synthase with a
C-terminally TAP-tagged F1 β-subunit [61]. In addition, we cloned green fluorescing protein
(GFP) into the tag to act as an additional reporter and for antibody-free localisation studies.
Fluorescence imaging (Fig 7A) confirms that both tagged subunits correctly localise to the
mitochondria.
Pulse-chase in vivo photo-affinity labelling with bi-functional compound 3 (and lead com-
pound 1 as negative control) was performed on cells from both cell lines expressing GFP-PTP-
tagged F1 α- or β-subunits. Tagged subunits were immobilised on IgG-sepharose beads, puri-
fied, and Cy5.5 fluorescent reporter clicked on, and proteins were detected by western blotting
(Fig 7B). Mouse anti-GFP coupled with anti-mouse-DyLight-800 identified tagged F1 α-
GFP-PTP and F1 β-GFP-PTP subunits migrating as expected at approximately 89 KDa and
101 KDa respectively. In trypanosomatids (but not in other organisms) the native α-subunit is
expressed as a 63 KDa protein which is then cleaved by an unknown protease to 20 KDa N-ter-
minal and 43 KDa C-terminal domains, both of which remain associated with the FoF1-ATP
synthase complex [61,62]. Pleasingly the 109 KDa GFP-PTP C-terminally tagged α-subunit
also appears to be cleaved at the same position yielding the 89 KDa GFP-PTP-tagged C-termi-
nal domain of the α-subunit, indicating that it is localised and processed within the cell as the
native untagged protein. Fig 7B shows that approximately equal amounts of GFP-PTP-tagged
protein had been captured between compound 1/3 pairs and between α- and β-subunits (Fig
7B), indicating that α- and β-subunits were expressed (and captured) to similar levels. How-
ever, for both α- and β-subunits, Cy5.5 fluorescence at 700 nm was only detected appreciably
in samples photo-affinity labelled with bi-functional compound 3, and not with lead com-
pound 1. This indicates that compound 3 can UV-conjugate to both F1 α- and β-subunits and
corroborates their pull-down in Table 1.
B-THP-Ts model to the F1 α- and β-subunit ATP-binding sites
F1 of mitochondrial complex V is a multi-protein complex composed of α-, β-, γ-, δ- and ε-sub-
units with stoichiometry 3:3:1:1:1 [63,64]. The α- and β-subunits form a catalytic heterohexamer
of alternating subunits with ADP/ATP binding sites at their interfaces (S2 Fig and Fig 8A and
8B) while γ- and ε-subunits form an asymmetrical central stalk connected to the Fo moiety
which together, driven by the proton-motive force, rotate within the α/β hexamer to drive ATP
production by introducing conformational changes at the catalytic sites and changing their
affinities for ADP and ATP [63,65–67]. X-ray crystal structures of F1 have been determined for
several species, but no high-resolution structure of trypanosomatid F1 have been solved. Conse-
quently, to determine likely B-THP-T binding sites over the entire F1 moiety, B-THP-T com-
pound 1, which displays only modest selectivity towards T. brucei over mammalian HeLa cells
(Fig 1), was docked into the entire F1 crystal structures from Sacharomyces cerevisiae (PDB
entry 2WPD [68]) and Bos taurus (PDB entry 1BMF [63]) using AutoDock Vina [69]. For both
crystal structures, catalytic and regulatory ATP binding sites were identified as sites of lowest
binding energy and therefore most likely binding positions of B-THP-T compounds.
The F1 α- and β-subunits are paralogues of one another with sequence identity of 20–25%
(value depending on species), and while the β-subunit has catalytic activity, the α-subunit has
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Fig 7. B-THP-Ts bind to C-terminal GFP-PTP tagged F1 α- and β- subunits. (A) Stably transfected PF T.
brucei cells endogenously-expressing F1 α-GFP-PTP or F1 β-GFP-PTP were loaded with MitoTracker Red
CMXros (red) and DAPI (blue) and imaged microscopically to determine localisation of GFP-PTP-tagged
protein. F1 α-GFP-PTP and F1 β-GFP-PTP were detected through natural fluorescence of their green
fluorescent protein (GFP) tag, and both were found to co-localise with MitoTracker, confirming their
mitochondrial association. (B) Following in vivo photo-affinity labelling with 50 μM compound 3 or
compound 1 (negative control), GFP-PTP-tagged F1 α- and β-subunits were affinity purified and Cy5.5
clicked on. Proteins were separated by SDS-PAGE and a western blot was performed with mouse anti-GFP /
anti-mouse-DyLight 800. GFP-PTP-tagged proteins were revealed at 800 nm, Cy5.5-bound target proteins at
700 nm, and a merged image shows both together. Lanes 1 and 2 used compounds 1 and 3 respectively
with F1 α-GFP-PTP-expressing cells and captured F1 α-GFP-PTP migrating at 89 KDa was observed with
anti-GFP at 800 nm in both lanes. F1 α-GFP-PTP only fluoresced at 700 nm when bi-functional compound 3
Bis-tetrahydropyran 1,4-triazoles target the FoF1-ATP synthase
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005886 September 5, 2017 15 / 28
lost this ability and instead plays a regulatory role in ATP synthesis and hydrolysis. They
share a common RecA-like protein fold along with other classes of ATP-binding proteins
including kinases, phosphatases, ATPases, heat shock proteins, transfer/transport ATPases,
and permeases [70,71], in which the adenine of the nucleotide binds within a sequence-non-
was used, indicating that Cy5.5 had bound specifically to the F1 α-subunit via our bi-functional photo-affinity
probe. Lanes 3 and 4 used compounds 1 and 3 respectively with F1 β-GFP-PTP-expressing cells, and
captured F1 β-GFP-PTP migrating at ~101 KDa was observed in both lanes with anti-GFP. As with the α-
subunit, β-GFP-PTP only conjugated Cy5.5 when the bi-functional compound 3 was used, confirming that
both the α- and β-subunits are targets of our B-THP-T compounds.
https://doi.org/10.1371/journal.pntd.0005886.g007
Fig 8. Binding of nucleotide and compound 1 to yeast F1 α- and β-subunits. Yeast F1 subunits are
oriented around the Walker A motif for comparisons. (A and B) The crystal structure yeast F1 with bound
nucleotide (PDB entry 2WPD [68]). ATP occupies that regulatory site of the α-subunit (A), while ADP occupies
the catalytic site of the β-subunit (B). The positioning of nucleotide is similar for both: the adenine anchors
within a hydrophobic pocket while the phosphates interact with the Walker A nest. Hydrogen bonds are shown
as dotted lines. (C-D) Docking of compound 1 into the yeast ATP binding sites. In the regulatory α-subunit
(C) the triazole moiety of compound 1 interacts with the Walker A nest, THP2 occupies the position of the
nucleotide ribose, the hydrophobic tail buries into the hydrophobic adenine pocket, and the terminal hydroxyl
forms extensive H-bonds. The position is compound 1 is different in β-subunit (D), whereby THP2 is
sandwiched between Tyr345 and Phe424, the hydrophobic tail buries into the adenine site, and THP1 and
terminal hydroxyl form potential H-bonds. (E) Compound 1.
https://doi.org/10.1371/journal.pntd.0005886.g008
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specific hydrophobic pocket and the B-phosphate within the amine nest of the conserved Walker
A motif (sequence GxxxxGKT/S) (Fig 8A and 8B). Although the mode of ATP-binding is simi-
lar for α- and β-subunits, their three-dimensional shapes differ due to differences in amino acid
sequence. The three ATP-binding regulatory sites of the α-subunits (top panel of S3A Fig) are
all relatively similar, however, the three ATP-binding catalytic sites of the β-subunits (lower
panel of S3A Fig) are different as their shapes are dependent on the position of the central stalk
(and thus state of bound nucleotide). The most significant differences are in the distances
between Tyr345 and Phe424, and in the position of the neighbouring α-subunit which completes
the catalytic site. The empty site of the β-subunit (βE) is open, while the ATP-bound (βTP) and
ADP + Pi-bound (βDP) conformations are closed and somewhat more similar to one another.
Compound 1 docked similarly within all three regulatory ATP-binding pockets of the yeast
α-subunits (αE, αDP and αTP, top panel of S4 Fig and Fig 8C). The triazole H-bonded with the
amine-rich phosphate nest, THP2 occupied a similar position to the ATP ribose and hydro-
phobic tail bound within the hydrophobic adenine-binding pocket. THP1 could potentially
form an H-bond via a water bridge, while the terminal hydroxyl could H-bond with Thr214,
Lys211 of the α-subunit or Ala327 of the neighbouring β-subunit. Interactions between com-
pound 1 and the bovine regulatory subunits were similar.
Compound 1 docked similarly within the nucleotide-bound β-subunits (βDP and βTP,
lower panel of S4 Fig and Fig 8D) of yeast F1 with THP2 sandwiched between Tyr345 and
Phe424 and the hydrophobic tail buried within the hydrophobic adenine-binding pocket lined
by V165, F166, P346 and F418. The triazole adopted a similar position to the nucleotide’s
ribose, allowing THP1 to sit close to the phosphate-binding Walker A nest and the terminal
hydroxyl to form extensive H-bonds with Pi-coordinating Arg190, Glu189, Arg260 and
Arg’375 (or Adp256 and Thr164). However, in the open BE conformation, Tyr345 and Phe424
lie too far apart to sandwich THP2 and the triazole instead forms interactions with the Walker
A nest and THPs potentially forming H-bonds via water bridges.
Docking of compound 1 to the ATP-binding sites of the α- and β-subunits reveals that
compound 1 can form similar interactions as ATP and suggests that B-THP-T compounds
mimic ADP, a finding which is mirrored by the pull-down of predominantly nucleotide utilis-
ing proteins during target identification (Table 1). Intriguingly, only one other protein (phos-
phoenolpyruvate carboxykinase–a glycosomal protein shown in S1 Table) identified as a
potential target during pull-down experiments has the Walker A motif, suggesting that the
B-THP-T compounds probably do not target all members of this protein family, but instead
bind to specific nucleotide-binding sites.
Conclusions
Until recently drug discovery efforts focussed on the identification of compounds targeting
proteins specific to the target organism with the view that such compounds would have low
toxicity to the human hosts. Such studies typically began with screening and lead optimisation
against recombinant target protein, but projects often derailed during subsequent cell-based
testing when compounds were shown to be equally toxic to mammalian cells or compounds
failed to reach their targets within the cells. Phenotypic screening removes all previous bias
towards targets and brings into play targets that were previously though undruggable by test-
ing compounds in their context within the cell. However, the major bottleneck in phenotypic
screening lies in identifying the target after initial screens, often making it difficult to further
improve compound potency and selectivity.
We previously identified compound 1 as a trypanocidal compound during phenotypic
screening and this study has successfully identified its protein target and mode of action using
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a photo-affinity labelling approach. Using a compound 1-like bi-functional photo-affinity
probe (compound 3), we showed that the target is localised to the mitochondria and biotin
pull-down experiments identified the α- and β-subunits of the FoF1-ATP synthase (mitochon-
drial complex V) as potential targets. We next used compound 1 to validate our photo-affinity
labelling experiments and showed that compound 1 inhibits cellular ATP production by
blocking oxidative phosphorylation at the FoF1-ATP synthase. Photo-affinity labelling with bi-
functional compound 3 confirmed that both α- and β-subunits are targeted and modelling
suggests that compound 1 binds at their ATP-binding regulatory and catalytic sites respec-
tively. While it is possible that both sites could be targeted, it must be noted that regulatory
and catalytic sites sit at the interfaces between α- and β-subunits and it may therefore be possi-
ble for photo-affinity probe compound 3 to covalently bind both of the subunits from either
catalytic or regulatory site. Regardless, future investigations can target both sites to tailor new
compounds that bind specifically to each, and this study highlights the usefulness of photo-
affinity labelling in target identification for structure-based drug discovery.
The overall architecture of the FoF1-ATP synthase is well conserved among different spe-
cies. Although the α- and β-subunits of T. brucei F1 share 47% and 67% sequence identity
respectively with their mammalian homologues, structural differences exist between them. In
particular, the trypanosomatid α-subunit is cleaved into 20 KDa N-terminal and 44 KDa C-
terminal chains and the recent low-resolution structure of T. brucei FoF1 obtained by cryo-
electron tomography [62] suggests that this causes a major shift in the position of the α-sub-
unit within the complex with respect to the β-subunit. Crucially, as the catalytic and regulatory
binding sites are positioned at the interfaces between α- and β-subunits this is likely to have an
effect on the overall shapes and sizes of those sites and a high-resolution structure is warranted
to facilitate future structure-based drug design.
The essentiality of the mitochondrial respiration complexes in human hosts may make the
FoF1-ATP synthase (complex V) appear an unattractive target despite the possibility of signifi-
cant differences between human and trypanosomatid homologues. However, the mitochondrial
complexes are being investigated as targets in other diseases. For example, complex I-targeting
acetogenins have shown promise as anti-cancer agents in preclinical studies [25], while complex
V-targeting Bedaquiline has also recently been approved for the treatment of tuberculosis [72].
The FoF1 ATP synthase has been shown to be essential in both PF [61] and BSF [73,74] T.
brucei, although its role in each parasite form differs. In the procyclic form (and in mammalian
hosts), it is chiefly involved in oxidative phosphorylation whereby mitochondrial complexes
III and IV generate a mitochondrial membrane potential (Δψm) by exporting protons from the
mitochondrion during the electron transport chain (ETC), and mitochondrial complex V (the
FoF1 ATP synthase) generates ATP while pumping protons back in. Furthermore, the Δψm is
used for other functions, such as protein trafficking [75] and tRNA import [76]. BSF T. brucei
lacks much of the oxidative phosphorylation machinery (namely, complexes III and IV, [77])
as it generates sufficient ATP through glycolysis [78] and generates the essential Δψm by run-
ning FoF1-ATP synthase in reverse, hydrolysing ATP instead of producing it [73,79,80]. The
difference in function between mammalian and BSF T. brucei FoF1 ATP synthase (ATP pro-
duction versus mitochondrial membrane polarisation respectively) could be exploited for the
creation of synergistic drug combinations that do not affect the mammalian hosts.
Materials and methods
Cell culture and generation of stably transfected cell lines
PF double marker strain 29–13 were maintained as reported previously [81] in full growth
medium (SDM-79 medium supplemented with 10% foetal bovine serum (FBS) (Gibco), 2 g/L
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sodium bicarbonate, 7.5 mg/L haemin,15 μg/mL neomycin (G418) and 50 μg/mL hygromycin)
at 27˚C with 5% CO2. For experiments using low-glucose growth medium, PFs were adapted
to glucose-free SDM-79 supplemented with 10% FBS, 2 g/L sodium bicarbonate, 7.5 mg/L hae-
min and maintained as above.
Subunit-GFP-PTP vector construction. The terminal 735 nucleotides of the α-subunit
and β-subunit of complex V were PCR amplified using primers 5’-AATTGGGTACCCCATG
GTCACGGCTCCTGGAACGC / 5’- ATCTTCCTTAAGCTCGAGTCTAGACACTGCCCGC
TTACAAGAGTAG and 5’-GGTACCCCATGGCAAGATGTGCTTCTTTTTATCGAC / 5’-C
TCGAGTCTAGAGCTACTGGCTTGAGCAACACGG respectively, and GFP was PCR am-
plified using primers 5’- TCTAGACTCGAGAGCAAGGGCGAGGAGCTGTTCACC / 5’-AT
CTTCCTTAAGCTTGTACAGCTCGTCCATGCCGAGAGTG. To generate the GFP-PTP-
tagged α-subunit, α-subunit and GFP, PCR products were XhoI-digested, ligated together
and inserted into the pC-PTP vector [60] using restriction sites KpnI and BamHI. To generate
the GFP-PTP-tagged β-subunit, the α-subunit was exchanged for the β-subunit using NcoI
and XbaI restriction sites.
Transfection and selection of stable cell lines. Cell lines were generated as previously
reported [82,83]. Briefly, 107 PF cells (strain 29–13) were transfected with 10 μg MfeI-linear-
ised pC-F1α-GFP-PTP vector or BsmI-linearised pC-F1β-GFP-PTP vector using an Amaxa
electroporator and T-cell nucleofector kit (Lonza) as per the manufacturer protocol. Stable
transformants were selected in and maintained in full growth medium supplemented with
2 μg/mL puromycin at 27˚C with 5% CO2.
B-THP-T pulse-chase photo-affinity labelling
B-THP-T compounds. Synthesis of B-THP-T compounds in our laboratory was reported
previously: lead compound 1 (compound 23 in [17]); mono-functional compound 2, 4-
((5S,7S)-7-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-
1-yl)methyl)-6-oxa-1,2-diazaspiro[2.5]oct-1-en-5-yl)butan-1-ol (synthesis to be published
elsewhere); bi-functional compound 3, (4-((5S,7S)-7-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetra-
hydro-2H-pyran-2-yl)-1H-1,2,3-triazol-1-yl)methyl)-6-oxa-1,2-diazaspiro[2.5]oct-1-en-5-yl)-
N-(prop-2-yn-1-yl)butanamide (synthesis to be published elsewhere).
In vivo photo-activatable-cross-linking. During the pulse phase of the experiment, WT
PF cells were incubated with B-THP-T compound at 50 μM in full growth medium for 1 h.
Cells were washed in PBS to remove excess compound and cells were incubated in full growth
medium for an additional 30 min to chase uptaken compound to its target. Cells were washed
and suspended in PBS, prior to UV irradiation at 365 nm for 10 min at 100 W. Proteins were
MeOH/CHCl3-precipitated and stored at -20˚C until required.
Cycloaddition of Cy5.5 and detection. Azide probe was conjugated to alkyne-tagged pro-
tein as previously reported [84]. Briefly, Cy5.5 azide (Jena Bioscience) was added to B-THP-T-
cross-linked protein using the Click-iT Protein Reaction Buffer Kit (Thermo Fisher Scientific)
as per manufacturers protocols. Proteins were separated by SDS-PAGE using standard proto-
cols. Gels were imaged with an Odyssey Imaging System (Li-Cor) and Cy5.5 detected at 700
nm. Images were processed using Li-Cor Image Studio (Version 4.0).
B-THP-T cross-linked protein localisation. B-THP-T compounds were pulse-chased
and cross-linked to their targets in vivo as outlined above, but they were UV-irradiated in full
growth medium. Live UV-irradiated WT cells were probed with 100 nM MitoTracker Red
CMXRos (Thermo Fisher Scientific) for 20 min and unincorporated dye was washed away.
Cells were fixed in 4% paraformaldehyde (PFA) in PBS, adhered to poly-lysine-coated slides
and permeabilised with 0.1% TX-100 in PBS for 10 min. Cells were washed copiously with 2%
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bovine serum albumin (BSA) (Sigma) in PBS. Cy5.5 was added to inhibitor-cross-linked pro-
teins using the Click-iT Cell Reaction Buffer Kit (Thermo Fisher Scientific) as per manufactur-
ers protocols. Unincorporated Cy5.5 azide was removed by extensive washing with 2% bovine
serum albumin (BSA) in PBS. Coverslips were mounted with DAPI-containing Slow Fade Dia-
mond Antifade mounting medium (Thermo Fisher Scientific). Images were collected using a
Deltavision wide field fluorescent light microscope and processed using SoftWorX software.
DAPI was excited at 387 ± 6 nm and detected at 447 ± 30 nm; MitoTracker Red CMXRos was
excited at 560 ± 25 nm and detected at 624 ± 20 nm; and Cy5.5 was excited at 650 ± 7 nm and
detected at 684 ± 12 nm. Exposure settings were optimised for the sample with compound 3
and applied to all samples for image consistency.
Protein target pull-down and identification
Biotin pull-downs. B-THP-T compounds were cross-linked to proteins in 5 x 107 WT
cells as outlined above and total protein content extracted by MeOH/CHCl3-precipitation.
Compound 3 was used as the functional B-THP-T, while compound 1 or compound 2 were
used as non-reactive negative controls. Cross-linked pellets were solubilised in 1 mL pull-
down buffer (PBS, 0.1% SDS) and insoluble material removed by centrifugation. Supernatants
were added to 50 μl streptavidin agarose (Sigma) and agitated with end-over-end agitation for
1 h, at RT. Sticky proteins and endogenously biotinylated proteins were removed by centrifu-
gation. The supernatant was MeOH/CHCl3-precipitated and biotin azide (Sigma) added using
the Click-iT Protein Reaction Buffer Kit (Thermo Fisher Scientific). Proteins were MeOH/
CHCl3-precipitated to remove free biotin and pellets were resolubilised in 1 mL of pull-down
buffer. 20 μl of streptavidin agarose was added and incubated with end-over-end agitation for
1 h at 4˚C. Beads were pelleted by centrifugation and washed 4 times in PBS / 0.02% SDS to
remove non-bound proteins. Beads were then washed 6 times in 50 mM ammonium bicarbon-
ate to remove SDS for subsequent applications.
On-bead tryptic digest. Beads were pelleted and suspended in an equal volume of 10 mM
ammonium bicarbonate to create a 50% slurry. Trypsin (0.2 μg) was added and samples were
digested overnight at 37˚C. Samples were centrifuged for 5 min at 8000 rpm and the peptide-
containing supernatants recovered. Peptides were concentrated down to 5 μL with a SpeedVac
(ThermoSavant) and made up to 20 μL with loading buffer (98% water, 2% acetonitrile, 0.05%
trifluoroacetic acid). For each sample, half (10 μL) was analysed by LC-MSMS (see below).
LC-MSMS. Peptides were separated on an Acclaim PepMap 100 C18 trap and an Acclaim
PepMap RSLC C18 column (ThermoFisher Scientific), using a nanoLC Ultra 2D plus loading
pump and nanoLC as-2 autosampler (Eksigent). Peptides were eluted with a gradient of increas-
ing acetonitrile, containing 0.1% formic acid (5–40% acetonitrile in 15 min, 40–95% in a further 5
min, followed by 95% acetonitrile to clean the column, before re-equilibration to 5% acetonitrile).
The eluate was sprayed into a TripleTOF 5600 electrospray tandem mass spectrometer (ABSciex)
and analysed in Information Dependent Acquisition (IDA) mode, performing 200 msec of MS
followed by 100 msec MSMS analyses on the 15 most intense peaks seen by MS.
Protein identification. The MS/MS data files generated were analysed using the Mascot
algorithm (Matrix Science) against a database of T. brucei proteins extracted from NCBI
Sept2014 with trypsin as the cleavage enzyme, and 20 ppm peptide mass tolerance. B-THP-T
targets were identified by subtracting any proteins pulled down in the negative samples from
the list of proteins pulled down with the ‘active’ B-THP-T (compound 3). Also removed were
proteins with<3 significant peptide identifications, proteins with scores <100, and unnamed
proteins. Finally, proteins known not to localise within the T. brucei mitochondrion were
removed from the list of potential B-THP-T targets.
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ATP production assays in digitonin-permeabilised cells
ATP production assays were carried out in duplicate, and three independent assays were con-
ducted. Cells were digitonin-permeabilised as previously described [55]. Briefly, cells were
washed in PBS and permeabilised for 5 min at a density of 1x108 cells/mL in SoTE buffer (20
mM Tris.HCl (pH 7.5), 2 mM EDTA pH 7.5, 600 mM sorbitol) supplemented with 0.015% (w/
v) digitonin. Permeabilised cells were pelleted at 5000 g for 3 min at 4˚C and suspended to
8.4x107 cells/mL in ATP assay buffer (20 mM Tris.HCl (pH 7.4), 15 mM KH2PO4, 0.6 M sorbi-
tol, 10 mM MgSO4, 2.5 mg/mL fatty acid-free BSA.
ATP production assays were carried out in 75 μl volumes in 96-well plates with a final PF T.
brucei cell density of 6.7 x 107 cells/mL as previously reported [55]. Unless otherwise stated,
inhibitors were used at high concentration (exceeding their EC90 values in live cells) because
plating density was>1000-fold higher than with live cell EC50 determination and to ensure that
the target was fully inhibited. B-THP-Ts, antimycin A (AA) and oligomycin A (OA) were used
at 200 μM, Dinitrophenol (DNP) at 1 mM, malonate at 5 mM, rotenone at 100 μM and salicyl-
hydroxamic acid (SHAM) at 100 μM. 59.25 μL digitonin-permeabilised cells (prepared above)
were added to 0.75 μl inhibitor dissolved in DMSO (or 0.75 μL DMSO without inhibitor for no
inhibitor control) and incubated for 10 min to allow inhibitors to take effect. Substrate was
added to 2.5 mM and incubated for 10 min. Reactions were started with the addition of ADP to
60 μM and incubated at RT for 30 min. Reactions were quenched by the addition of 1.75 μL of
60% perchloric acid and the plate was incubated on ice for 30 min. The acid was then neutral-
ised with 11.5 μL of 1 M KOH. ATP production was quantified using ATP bioluminescence
assay kit CLS II (Roche). 10–20 μL from each well was transferred in duplicate to a black
96-well plate. Volumes were made to 50 μL with 0.5 M Tris-acetate pH 7.75. 50 μL luciferase
was added to each well, mixed, and precise luminescence was recorded with a Spectramax Gem-
ini XPD (Molecular Devices) set to high sensitivity. Background luminescence was subtracted
from each well and ATP levels calculated relative to the uninhibited controls.
ATP monitoring in live PF cells
Effects of compounds on proline metabolism were determined using a methodology adapted
from Podolec et al [85]. Briefly, glucose-free-conditioned PF T. brucei cells were washed into
buffered PBS and incubated in 200 μl volumes with inhibitors for 10 min. 3 mM proline was
added as the sole carbon source and cells were incubated for 2 h, after which cultures were
spiked with 1 mM citric acid (as internal standard) and cells were pelleted. Supernatants con-
taining metabolic end-products and citrate standard were analysed to evaluate effects on pro-
line metabolism (see below), while the ATP content of cells was determined as follows. Cells
were resuspended in 75 μL PBS and lysed with the addition of 1.75 μL 60% perchloric acid.
Reactions were incubated on ice for 30 min, then neutralised with 11.5 μL 1 M KOH. ATP
content was determined as above.
MitoTracker-monitoring of mitochondrial membrane potential
Qualitative analysis. 2 x 106 PF T. brucei cells were incubated in 1 mL GF-SDM-79
growth media supplemented with/without inhibitors for 2 h. B-THP-Ts were used at 40 μM,
AA and OA at 2 μM, DNP at 1 mM and SHAM at 100 μM. MitoTracker Red CMXRos and
MitoTracker Green FM were added to 100 nM and 1 μM respectively and incubated for a fur-
ther 10 min. Cells were washed in growth medium and the MitoTracker reagents chased into
the mitochondrion for 10 min in fresh growth medium supplemented with inhibitors. Cells
were washed again in growth medium to remove unincorporated MitoTracker reagents, pel-
leted, suspended in 100 μL 4% PFA in PBS, and fixed at RT in the dark for 10 min. Fixed cells
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were pelleted and suspended in 100 μl PBS. Cells were transferred to poly-lysine-coated slides
and mounted with DAPI-containing SlowFade mounting medium (Invitrogen). Fluorescence
images were collected with a DeltaVision microscope (as detailed above) to show MitoTracker
localisation and comparative intensity.
Quantitative analyses. 1 mL of cells at 1 x 107 cells/mL were labelled as above. However,
instead of fixing cells they were resuspended in 200 μL growth medium and transferred to
96-well plates. Fluorescences were recorded (excitation at 540/35 nm, emission at 590/10 nm
for MitoTracker Red CMXRos, and excitation at 485/20 nm, emission at 528/20 nm for Mito-
Tracker Green FM) using a BioTek FLX800 spectrofluorimeter and Gen5 Reader Control 2.0
software, in much the same way as others have recorded previously [86–89]. Background fluo-
rescence values were subtracted from each and MitoTracker Red fluorescences normalised
against their MitoTracker Green FM counterparts. Membrane potentials were then calculated
relative to the uninhibited controls.
Purification of GFP-PTP-tagged F1 α- and β-subunits
F1 α- and β-subunits were purified using a similar procedure to that previously described for
TAP-tagged subunits [61]. Briefly, PF T. brucei cells from 50 mL culture endogenously express-
ing GFP-PTP-tagged F1 subunits were photo-affinity probed with 50 μM compound 3 or com-
pound 1 as outlined above, except cells were lysed in IP buffer (50 mM Tris.HCl (pH 7.6),
150 mM NaCl, 1% TX-100) supplemented with ‘Complete’ EDTA-free protease inhibitors
(Roche). GFP-PTP-tagged proteins were solubilsed for 1 h with end-over-end agitation at 4˚C
and insoluble material pelleted at 16000 g for 10 min at 4˚C. The supernatant was applied to
20 μL IgG-sepharose (GE Healthcare Life Sciences) and incubated with end-over-end agitation
for 1 h at 4˚C. Beads were pelleted at 16000 g for 1 min and non-bound material was discarded.
Beads were washed 4 times in 1 mL IP buffer to remove contaminating proteins.
On-bead cycloaddition of Cy5.5 and detection. Beads were washed 4 times into 50 mM
Tris.HCl pH 8.0 and Cy5.5 azide (Jena Bioscience) was conjugated to immobilised B-THP-T-
cross-linked GFP-PTP-tagged protein using the Click-iT Protein Reaction Buffer Kit (Thermo
Fisher Scientific) as per manufacturers protocols. Immediately following cycloaddition, beads
were washed 4 times in IP buffer to remove reactants and proteins were eluted from the beads
directly into reducing SDS-PAGE sample buffer. Proteins were separated by SDS-PAGE using
standard protocols and transferred to nitrocellulose. Blots were probed with mouse anti-GFP
(Roche) and anti-mouse-DyLight-800 (Thermo) and imaged with an Odyssey Imaging System
(Li-Cor). Cy5.5-conjugated proteins were detected at 700 nm, while GFP-tagged proteins were
detected at 800 nm. Images were processed using Li-Cor Image Studio (Version 4.0).
In silico docking of compound 1 to F1
Compound 1 was docked into F1 from Bos taurus (PBD entry 1BMF [63]) and Saccharomyces
cerevisiae (PDB entry 2WPD [68]) using AutoDock Tools [90] and AutoDock Vina [69] as
per the user manuals. Briefly, the energy-minimised 3-dimensional coordinates of compound
1 were generated with ChemBio 3D (Perkin Elmer) and converted to PDBQT format with
AutoDockTools. All non-protein atoms (e.g., waters, nucleotides and metals) were removed
from the F1 PDB coordinates and hydrogens were added with AutoDockTools. Initially com-
pound 1 was docked into the entire F1 complex using a grid-box of dimensions 126 x 126 x
126 Å containing the entire complex and an exhaustiveness of 48 to account for the large
search area. Compound 1 was next docked into the ATP-binding sites of each α- and β-sub-
unit using a grid-box of dimensions 17 x 15 x 23 Å covering the binding site. Positions of
docked compound 1 were evaluated using Pymol (Schrodinger).
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Supporting information
S1 Fig. Dose-response of B-THP-T compounds in PF T. brucei. EC50 values were deter-
mined for compounds 1–3 in PF T. brucei. Compounds had similar potencies, indicating that
the tags for photo-affinity labelling have no detrimental effect.
(TIFF)
S2 Fig. Architecture of the FoF1-ATP synthase. The crystal structure of ATP synthase from
yeast (PDB entry 2WPD [68]) is shown.
(A) α- and β-subunits form a heterohexameric catalytic domain. Driven by the protonmotive
force, the asymmetrical γ/δ/ε stalk and Fo domains rotate within the catalytic domain, provid-
ing mechanical power to generate ATP.
(B) Cross-section of the α/β hexamer. ATP binding sites at the subunit interfaces. ATP in reg-
ulatory sites is coloured magenta, ADP in catalytic sites is coloured purple.
(TIFF)
S3 Fig. Structures of the ATP-binding sites of yeast F1 subunits. Yeast F1 subunits, oriented
around the Walker A motif, with bound nucleotide. The position of the nucleotide is similar
for each subunit despite sequence differences between α- and β-subunits. Large shifts in the
position of adjacent subunits can be seen in the catalytic sites (lower images), where R’375 and
S’374 move in to close the active site around the bound nucleotide. The regulatory site (upper
images) remains relatively unchanged during catalysis.
(TIFF)
S4 Fig. Structures of the ATP-binding sites of yeast F1 subunits docked with compound 1.
Yeast F1 subunits, oriented around the Walker A motif, with docked compound 1. Com-
pound 1 docks similarly into each of the α-subunit regulatory sites, which are all similar in
structure. The triazole moiety interacts with the Walker A nest, THP2 occupies the position of
the nucleotide ribose, hydrophobic tail buries into the hydrophobic adenine pocket, and the
terminal hydroxyl forms extensive H-bonds. The position is different in β-subunits. In the
nucleotide-bound sites THP2 is sandwiched between Tyr345 and Phe424, the hydrophobic tail
buries into the adenine site, and THP1 and terminal hydroxyl form potential H-bonds. In the
open catalytic site of βE Tyr345 and Phe424 lie too far apart to hold THP2 and compound 1
adopts a different position.
(TIFF)
S1 Table. Proteins identified as potential targets of B-THP-T compounds by biotin pull-
down / LC-MSMS—complete list. a Predicted location: C, cytosolic; G, glycosomal; M, mito-
chondrial; F, flagellar.
(DOCX)
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